Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer

Starting in 2014, large phase III clinical trials began to disclose the study results of using programmed death (PD)-1 immune checkpoint inhibitors (ICIs) (pembrolizumab, nivolumab) and PD-ligand (L)1 (atezolizumab, durvalumab, avelumab) ICIs immunotherapy in patients with advanced head and neck squ...

Descripción completa

Detalles Bibliográficos
Autor principal: Kok, Victor C.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2020
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7058818/
https://www.ncbi.nlm.nih.gov/pubmed/32185135
http://dx.doi.org/10.3389/fonc.2020.00268

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7058818/
https://www.ncbi.nlm.nih.gov/pubmed/32185135
http://dx.doi.org/10.3389/fonc.2020.00268

Ejemplares similares